Literature DB >> 18800204

Investigation of the metabolites of (S,S)-[(11)C]MeNER in humans, monkeys and rats.

Magnus Schou1, Sami S Zoghbi, H Umesha Shetty, Evgeny Shchukin, Jeih-San Liow, Jinsoo Hong, Bengt A Andrée, Balázs Gulyás, Lars Farde, Robert B Innis, Victor W Pike, Christer Halldin.   

Abstract

INTRODUCTION: (S,S)-[(11)C]MeNER ((S,S)-2-(alpha-(2-[(11)C]methoxyphenoxy)benzyl)morpholine) is a positron emission tomography (PET) radioligand recently applied in clinical studies of norepinephrine transporters (NETs) in the human brain in vivo. In view of further assessment of the suitability of (S,S)-[(11)C]MeNER as a NET radioligand, its metabolism and the identity of the in vivo radiometabolites of (S,S)-[(11)C]MeNER are of great interest.
MATERIALS AND METHODS: Thus, PET studies were used to measure brain dynamics of (S,S)-[(11)C]MeNER, and plasma reverse-phase radiochromatographic analysis was performed to monitor and quantify its rate of metabolism. Eighteen healthy human volunteers, five cynomolgus monkeys, and five rats were studied. RESULTS AND DISCUSSION: In human subjects, the plasma radioactivity representing (S,S)-[(11)C]MeNER decreased from 88 +/- 5% at 4 min after injection to 82 +/- 7% at 40 min, while a polar radiometabolite increased from 3 +/- 3% to 16 +/- 7% at the same time-points, respectively. A more lipophilic radiometabolite than (S,S)-[(11)C]MeNER decreased from 9 +/- 5% at 4 min to 1 +/- 2% at 40 min. In monkeys, plasma radioactivity representing (S,S)-[(11)C]MeNER decreased from 97 +/- 2% at 4 min to 74 +/- 7% at 45 min, with a polar fraction as the major radiometabolite. A more lipophilic radiometabolite than (S,S)-[(11)C]MeNER, constituted 3 +/- 2% of radioactivity at 4 min and was not detectable later on. In rats, 17 +/- 4% of plasma radioactivity was parent radioligand at 30 min with the remainder comprising mainly a polar radiometabolite. (S,S)-[(11)C]MeNER in rat brain and urine at 30 min after injection were 90% and 4%, respectively. On a brain regional level, parent radioligand ranged from 87.5 +/- 3.9% (57.2 +/- 14.2% SUV [standard uptake values, %injected radioactivity per mL multiplied with animal weight (in g)]; cerebellum) to 92.9 +/- 1.8% (36.1 +/- 4.7% SUV; striatum), with differential distribution of the radiometabolite in the cerebellum (6.7 +/- 0.3% SUV) and the striatum (2.5 +/- 0.3% SUV). Liquid chromatography-mass spectrometry analysis of rat urine identified a hydroxylation product of the methoxyphenoxy ring of (S,S)-MeNER as the main metabolite. In the brain, the corresponding main metabolite was the product from O-de-methylation of (S,S)-MeNER. PET measurements were performed in rats as well as in wild-type and P-gp-knock-out mice. In rats, the brain peak level of radioactivity was found to be very low (65%SUV). In mice, there was only a small difference in peak brain accumulation between P-gp knock-out and wild-type mice (145 vs. 125%SUV) with the following rank order of regional brain radioactivity: cerebellum x thalamus > cortical regions > striatum.
CONCLUSION: It can be concluded that radiometabolites of (S,S)-[(11)C]MeNER are of minor importance in rat and monkey brain imaging. The presence of a transient lipophilic radiometabolite in peripheral human plasma may induce complications with brain imaging, but its kinetics appear favorable in relation to the slow kinetics of (S,S)-[(11)C]MeNER in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800204      PMCID: PMC2789463          DOI: 10.1007/s11307-008-0175-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  16 in total

1.  Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter.

Authors:  Alan A Wilson; David Patrick Johnson; David Mozley; Doug Hussey; Nathalie Ginovart; Jose Nobrega; Armando Garcia; Jeffery Meyer; Sylvain Houle
Journal:  Nucl Med Biol       Date:  2003-02       Impact factor: 2.408

2.  Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes.

Authors:  L C Wienkers; C Allievi; M J Hauer; M A Wynalda
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

3.  Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals.

Authors:  D D Dishino; M J Welch; M R Kilbourn; M E Raichle
Journal:  J Nucl Med       Date:  1983-11       Impact factor: 10.057

Review 4.  Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor.

Authors:  P Dostert; M S Benedetti; I Poggesi
Journal:  Eur Neuropsychopharmacol       Date:  1997-04       Impact factor: 4.600

5.  Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER.

Authors:  Magnus Schou; Christer Halldin; Judit Sóvágó; Victor W Pike; Balázs Gulyás; P David Mozley; David P Johnson; Håkan Hall; Robert B Innis; Lars Farde
Journal:  Nucl Med Biol       Date:  2003-10       Impact factor: 2.408

6.  Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography.

Authors:  G A Donnan; S J Kaczmarczyk; G Paxinos; P J Chilco; R M Kalnins; D G Woodhouse; F A Mendelsohn
Journal:  J Comp Neurol       Date:  1991-02-15       Impact factor: 3.215

7.  Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs.

Authors:  Yu-Shin Ding; Kuo-Shyan Lin; Victor Garza; Pauline Carter; David Alexoff; Jean Logan; Colleen Shea; Youwen Xu; Payton King
Journal:  Synapse       Date:  2003-12-15       Impact factor: 2.562

8.  PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.

Authors:  Sami S Zoghbi; H Umesha Shetty; Masanori Ichise; Masahiro Fujita; Masao Imaizumi; Jeih-San Liow; Jay Shah; John L Musachio; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

9.  [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding.

Authors:  S M Tejani-Butt
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

10.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Authors:  A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

View more
  7 in total

Review 1.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study.

Authors:  Robert Risinger; Zubin Bhagwagar; Feng Luo; Matthew Cahir; Laura Miler; Anisha E Mendonza; Jeffrey H Meyer; Ming Zheng; Wendy Hayes
Journal:  Psychopharmacology (Berl)       Date:  2013-12-15       Impact factor: 4.530

3.  Motion-artifact-free in vivo imaging utilizing narcotized avian embryos in ovo.

Authors:  Alexander Heidrich; Lydia Würbach; Thomas Opfermann; Hans Peter Saluz
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

4.  Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [(11)C]ME@HAPTHI.

Authors:  Christina Rami-Mark; Neydher Berroterán-Infante; Cecile Philippe; Stefanie Foltin; Chrysoula Vraka; Alexander Hoepping; Rupert Lanzenberger; Marcus Hacker; Markus Mitterhauser; Wolfgang Wadsak
Journal:  EJNMMI Res       Date:  2015-06-10       Impact factor: 3.138

5.  Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter.

Authors:  Catharina Neudorfer; Amir Seddik; Karem Shanab; Andreas Jurik; Christina Rami-Mark; Wolfgang Holzer; Gerhard Ecker; Markus Mitterhauser; Wolfgang Wadsak; Helmut Spreitzer
Journal:  Molecules       Date:  2015-01-20       Impact factor: 4.411

6.  Synthesis of [11C]carbonyl-labeled cyclohexyl (5-(2-acetamidobenzo[d]thiazol-6-yl)-2-methylpyridin-3-yl)carbamate ([11C-carbonyl]PK68) as a potential PET tracer for receptor-interacting protein 1 kinase.

Authors:  Tomoteru Yamasaki; Katsushi Kumata; Atsuto Hiraishi; Yiding Zhang; Hidekatsu Wakizaka; Yusuke Kurihara; Nobuki Nengaki; Ming-Rong Zhang
Journal:  EJNMMI Radiopharm Chem       Date:  2022-03-15

7.  [11C]MADAM Used as a Model for Understanding the Radiometabolism of Diphenyl Sulfide Radioligands for Positron Emission Tomography (PET).

Authors:  Fabienne Gourand; Nahid Amini; Zhisheng Jia; Sharon Stone-Elander; Denis Guilloteau; Louisa Barré; Christer Halldin
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.